COLL
Collegium Pharmaceutical Inc
22.60$
+0.8%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 45.6% | 47.0% | 48.4% | 48.4% | 27.1% | 29.0% | 32.3% | 34.5% | 38.2% | 41.7% | 45.1% | 28.5% | |
| 22.0% | 20.9% | 20.5% | 16.4% | 2.4% | 4.2% | 5.9% | 7.4% | 10.6% | 15.2% | 16.3% | 6.1% | |
| 25.9% | 27.2% | 28.5% | 25.8% | 7.3% | 9.8% | 12.1% | 13.9% | 19.0% | 24.5% | 25.5% | 6.1% | |
| 15.4% | 15.7% | 15.7% | 17.5% | 14.0% | 13.7% | 14.0% | 13.4% | 14.6% | 12.8% | 13.8% | 13.3% | |
| 2.9% | 2.8% | 2.8% | 2.6% | 2.3% | 2.1% | 2.3% | 2.4% | 2.4% | 2.5% | 2.6% | 5.3% | |
| 11.4% | 11.7% | 12.0% | 12.7% | 8.9% | 9.8% | 9.2% | 9.3% | 9.1% | 8.8% | 8.8% | 8.9% | |
| 38.7% | 36.9% | 34.7% | 33.5% | 57.9% | 53.6% | 51.2% | 49.0% | 45.1% | 40.4% | 37.2% | 55.5% | |
| 84.8% | 82.9% | 80.1% | 79.4% | 85.7% | 86.2% | 85.6% | 85.4% | 82.9% | 81.8% | 81.1% | 85.4% | |
| 39.5% | 40.1% | 40.1% | 43.8% | 28.1% | 30.6% | 29.8% | 29.2% | 28.2% | 26.6% | 26.3% | 27.6% | |
| 15.7% | 16.1% | 16.5% | 17.5% | 4.0% | 4.0% | 4.0% | 4.1% | 4.1% | 1.8% | 2.1% | 2.6% | |
| 0.3% | 0.8% | 0.5% | 0.2% | 0.2% | 0.2% | 1.1% | 0.7% | 0.5% | 0.6% | 0.4% | 0.4% | |
| 44.8% | 42.3% | 39.5% | 35.1% | 49.1% | 47.4% | 47.4% | 47.6% | 46.3% | 47.1% | 46.6% | 48.5% | |
| 15.2% | 17.1% | 19.9% | 20.6% | 14.3% | 13.8% | 14.4% | 14.6% | 17.1% | 18.2% | 18.9% | 14.6% | |
| -22.5% | -20.4% | -18.4% | -17.6% | -10.8% | -9.9% | -9.9% | -9.4% | -7.3% | -6.1% | -5.2% | -4.8% | |
| 3.6% | 3.7% | 3.7% | 3.8% | 2.5% | 2.4% | 2.0% | 2.5% | 2.5% | 2.4% | 2.4% | 1.5% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.